SERB Pharmaceuticals has acquired exclusive rights to develop and sell Idefirix (imlifidase), a treatment for highly sensitised kidney transplant patients, across Europe and the MENA region from Hansa Biopharma for €115 million. Idefirix helps reduce antibodies that cause organ rejection, addressing a critical need for patients who face long waits for compatible kidney transplants. The deal includes upfront and milestone payments to Hansa, with SERB taking over regulatory filings and ongoing studies. This acquisition expands SERB's portfolio in rare and urgent medical conditions and aims to improve transplant access for underserved patients.
Samsung Wallet will launch a new stablecoin feature in late October 2026, available on 82 million U.S. Galaxy devices, allowing users to hold and send stablecoins without separate apps or managing private keys. Bastion, selected as the licensed custo...
The crypto market declined recently due to three main factors: significant outflows from US Bitcoin and Ether spot ETFs, forced liquidation of $651 million in long futures positions, and Federal Reserve minutes indicating a likely further interest ra...
Paxos has integrated XRP into its regulated Crypto Brokerage platform, enabling businesses using its infrastructure to offer XRP for buying, selling, holding, deposits, and withdrawals. This update expands Paxos' asset roster to 29 and supports over ...
Europol's European Cybercrime Centre reports that Bitcoin's blockchain remains secure against quantum computing attacks due to its hash functions. However, about 30% of Bitcoin, roughly 6 to 6.9 million BTC, is held in wallets with exposed public key...
Novo Nordisk is rated as a Buy compared to Eli Lilly because it trades at a significant valuation discount of about 26% to its big pharma peers despite having similar growth rates and a strong dividend yield. The stock is priced at roughly 11.2 times...
